Journal
INFLAMMOPHARMACOLOGY
Volume 31, Issue 1, Pages 321-335Publisher
SPRINGER BASEL AG
DOI: 10.1007/s10787-022-01104-w
Keywords
Rheumatoid arthritis; Endothelial dysfunction; Atherosclerosis; VCAM-1; alpha-SMA
Categories
Ask authors/readers for more resources
The conjugation of methotrexate to gold nanoparticles showed significant improvement in rheumatoid vascular dysfunction, highlighting the potential of nanoparticles-targeted drug delivery system in treating cardiovascular diseases in rheumatoid arthritis patients.
Endothelial vasomotor dysfunction and accelerated atherosclerosis encompass the features of rheumatoid vascular dysfunction (RVD), increasing cardiovascular morbidity and mortality among rheumatoid arthritis (RA) patients. Methotrexate, among DMARDs, effectively reduces cardiovascular events, but its non-selectivity together with its pharmacokinetic variability often limit drug adherence and contribute to its potential toxicity. Thus, methotrexate was conjugated to gold nanoparticles (MTX/AuNPs) and its effect on RVD in rats' adjuvant-induced arthritis was evaluated. A comparative study between MTX/AuNPs, free MTX, and AuNPs treatments on joint inflammation, vascular reactivity and architecture, smooth muscle phenotype, systemic inflammation, and atherogenic profile was done. Since MTX/AuNPs effect was superior, it appears that conjugation of MTX to AuNPs demonstrated a synergistic action. MTX immunomodulatory action combined with AuNPs anti-atherogenic potential yielded prompt control of whole features of RVD. These findings highlight the usefulness of nanoparticles-targeted drug-delivery system in refining rheumatoid-induced vascular dysfunction treatment and reviving gold use in RA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available